BioNTech (BNTX) Stock
Fundamentals
Latest news
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board | 1965 |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 1967 |
| Mr. Ramon Zapata-Gomez | CFO & Member of Management Board | 1974 |
| Dr. Sierk Pötting Ph.D. | MD, COO & Member of Management Board | 1973 |
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal & Business Officer and Member of the Management Board | 1975 |
| Ms. Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board | 1980 |
| Ms. Kylie Jimenez | Chief People Officer & Member of Management Board | 1976 |
| Ms. Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting | — |
| Mr. Douglas Maffei Ph.D. | Vice President of Strategy & Investor Relations | — |
| Jasmina Alatovic | Vice President Corporate Communications | — |



